Compliance Support for 21 CFR Part 1271 Including HCT/P Human Cell and Tissue Products
Developing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) and related medical devices or biologics involves a complex, high-stakes regulatory path. Ensuring donor safety, product sterility, and compliance with diverse global regulations—including the requirements of 21 CFR Part 1271—is paramount.
NAMSA, as the global leader in MedTech development solutions, is offering the comprehensive domain expertise and integrated services you need to successfully navigate your HCT/P lifecycle, from concept through commercialization while driving commercial success. Don’t let regulatory, reimbursement, or clinical adoption challenges slow your innovation from getting to market.
Comprehensive HCT/P Testing and 21 CFR Part 1271 Compliance Services
Robust, compliant preclinical and clinical testing is the foundation for demonstrating the safety and effectiveness of any HCT/P product. NAMSA’s state-of-the-art laboratories in the US deliver the critical testing required for product submissions and ongoing quality assurance. Our clinical research services can support gathering the pivotal data you need to secure marketing authorization, payer coverage, and clinical adoption.
Integrated Preclinical, Clinical and Consulting Support for HCT/P Products
NAMSA offers a full continuum of preclinical and clinical research, regulatory and reimbursement support, minimizing the delays and risks associated with managing multiple vendors for different activities.
Preclinical Research
Our GLP-compliant and AAALAC-accredited facilities offer unparalleled support for HCT/P safety and performance evaluation.
- Customized Study Design: We design preclinical studies tailored to your HCT/P’s unique characteristics and regulatory pathway (e.g., device, biologic, or combination product), and support and provide documents for regulatory interactions. Our comprehensive services involve consulting support for preclinical study design, biocompatibility plans, and regulatory support during the process. We ensure our laboratories are involved in the process to ensure critical requirements by regulatory agencies are included in the study conduct.
- Safety and Effectiveness Models: We utilize our deep expertise within our laboratory and consulting services which span across therapeutic areas to generate the robust data required for regulatory submissions.
Specialized Testing
NAMSA offers a wide variety of testing for HCT/P products including:
Sterility and Microbiological Testing: Essential for patient safety, we provide comprehensive services, including:
- Sterility Testing (USP <71>, ANSI/AAMI/ISO 11737-2 and other global standards)
- Bacterial Endotoxin Testing (LAL: USP <85> and ANSI/AAMI/ISO 11737-3)
- Bioburden Testing (ANSI/ AAMI/ ISO 11737-1)
- Custom Microbiology testing, including, but not limited to, kill time testing and disinfection efficacy validations.
Biocompatibility and Biological Safety: For HCT/Ps regulated as medical devices, biological products or pharmaceutical products, our experts design and execute full ISO 10993 compliant testing strategies (including cytotoxicity, sensitization and irritation,) to evaluate the product’s interaction with the human body.
Histopathology Services: Our in-house histologists and pathologists provide expert evaluation of tissue response to implanted HCT/Ps and related materials, a vital component of preclinical safety assessment conducted at NAMSA laboratories.
Clinical Research
Our global Clinical Research Organization (CRO) has all the capabilities you need to manage your HCT/P clinical trials efficiently and compliantly.
- Trial Strategy and Design: We provide strategic guidance on study protocol development, investigational site selection, and investigator engagement tailored for HCT/P and cell/tissue-based product investigations.
- Global Clinical Operations: We leverage our deep expertise in managing all phases of clinical trials to collect high-quality data, generate impactful, focused reports, and maintain regulatory compliance.
Regulatory Consulting
Our highly qualified regulatory experts simplify the path to market by providing strategic guidance and support tailored to your product and target market.
- Product Classification: We work with you to determine the correct risk classification for your HCT/P, whether under US requirements in 21 CFR Part 1271 (including Section 361 vs. Section 351 considerations), or in the EU in accordance with the Medical Device Regulation (EU 2017/745).
- Regulatory Pathway: We will partner with you to devise the least burdensome, most efficient regulatory pathway for your HCT/P. This includes:
- Developing multi-region (EU and US) strategies to minimize duplication and accelerate approvals.
- Mapping timelines, costs, and evidence requirements to reduce risk.
- Identifying opportunities for expedited programs (such as Breakthrough Device Designation)
- Combination Product Considerations: For products that combine cells/tissues with devices or drugs, we will assist you with navigating the FDA’s Office of Combination Products and in Europe the borderlines with the Medical Device Regulation (EU 2017/745) and the European Medicines Agency’s (EMA) Advanced Therapy Medicinal Product (ATMP) to ensure proper regulatory alignment.
- Biological Evaluation Plan, Report and Strategy: NAMSA can help you craft a full plan that will comply with FDA, EU and international requirements.
- Our team provides expert assistance with regulatory agency communication, documentation preparation, and regulatory filings, including pre-submission meetings, Premarket Approval, 510(k) clearance, and De Novo requests
- Compliance with all aspects of 21 CFR Part 1271, including donor eligibility and Good Tissue Practice (GTP) requirements
- EU MDR technical documentation and notified body dialogue
Reimbursement
Entering the market is only the first step on the path to commercial success. Without payer coverage, even the most innovative therapies face barriers to adoption.
For HCT/Ps reimbursement can be particularly complex. The regulatory and reimbursement landscape is evolving rapidly, and coding frameworks are continually shifting.
We work with you to define a successful pathway to achieving reimbursement coverage. From leveraging existing codes to developing novel codes through unique mechanisms such as Coverage with Evidence Development. We will guide you through each step. We will also conduct in-depth research on payer expectations and evidence development strategies to strengthen your case for coverage and ensure your cell and tissue-based therapies have the best chance of adoption.
Meet NAMSA’s Team of HCT/P Experts
Human cell and tissue products require very specialized knowledge and lab capabilities.
-
Shazia A. Siddiqui, MS, NRCM
Principal MicrobiologistView Bio -
Jayshree Patel, MBA, PhD
Sr. Manager – Laboratory Technical ServicesView Bio -
Jane Arnold-Round, MSc
Senior Principal Consultant, RegulatoryView Bio -
Monica R. Montañez, MS, RAC, CQA
Principal Strategy Consultant, RegulatoryView Bio -
Jack Risdahl, DVM, PhD
Principal Strategy Consultant, PreclinicalView Bio
Access to Key Opinion Leaders
In addition to our team listed above, NAMSA gives you exclusive access to KOLs who have pioneered transformative approaches in cardiac tissue engineering, advancing cell delivery methods, creating composite-based cardiac patches with integrated microvascular networks, and exploring novel scaffolds such as decellularized plant tissues for perfusable human cell culture. This depth of experience ensures your program benefits from cutting-edge insights and proven methodologies.
Why Choose NAMSA for 21 CFR Part 1271 and HCT/P Compliance Services?
- Integrated, End-to-End Solutions: Get all your preclinical, clinical, and regulatory needs met by a single, trusted partner.
- Unmatched Regulatory Insight: Our consultants include regulatory reviewers who deeply understand the nuances of HCT/P classification and submission requirements.
- Full Support Through Commercial Success: Our reimbursement consultants get your product covered for payment and help ensure clinical adoption.
- Nationwide Laboratory Capacity: With 3 testing facilities across the U.S., we offer scalable support and geographic flexibility to meet your needs
- Extensive Experience Across Tissue Types: We have supported testing and compliance for a wide range of human cells, tissues, and cellular and tissue-based products (HCT/Ps), including—but not limited to—bone, cartilage, connective tissue, amniotic tissue, soft tissue, dermis, and heart valves.
- Time-Sensitive Testing for Critical Procedures: We collaborate closely with clients and clinicians to deliver rapid testing solutions that support urgent surgical timelines, ensuring patient safety and procedural success.
- Time-to-Market Focus: Our streamlined processes and deep expertise are designed to maximize success and accelerate your product’s journey to the patient.
Ready to de-risk your HCT/P program and ensure your commercial success?
Other Services That May Interest You
Animal Tissue Device Support
Biological Evaluation Plans and Reports
